Navigation Links
Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
Date:1/9/2012

GENEVA, Jan. 9, 2012 /PRNewswire/ -- Selexis SA announced today the appointment of Yemi Onakunle, Ph.D., M.B.A. as Vice President of Strategic and Market Development.

Dr. Onakunle will report directly to President and CEO, Dr. Igor Fisch and will be responsible for expanding Selexis' presence in the drug discovery, next generation biologics and difficult-to-express protein markets.

"Selexis is experiencing a tremendous growth cycle by offering more innovation and long-term value to our customers. Yemi's wealth of business development and sales experience in biologics and cell line development will be instrumental in expanding the SUREtechnology Platform™ into important markets," said Dr. Igor Fisch, CEO of Selexis. "Yemi's understanding of our technology and expanding global customer base makes him an excellent choice for this newly created position."

Dr. Onakunle has over 15 years' experience in drug manufacturing and cell line development. Prior to working at Selexis, Dr. Onakunle was Director of Commercial Development at Diosynth RTP Inc. and Associate Director of Business Development at Lonza Custom Manufacturing – organizations providing process development and cGMP manufacturing services in mammalian production platforms. More recently, Dr. Onakunle was Head of Sales and Marketing at Bachem Americas Inc. - a contract manufacturing organization focusing on peptides and complex organic molecules. In these positions, he has a strong record of consistently growing the customer base and sales and expanding product offerings into new markets. Dr. Onakunle is a member of the Board of Directors of VLP Biotech Inc, a vaccine development company based in San Diego, CA and has been a Business Advisor to several biopharmaceutical and drug delivery companies. Educated in the UK, Dr. Onakunle holds a Ph.D. from the University of Kent at Canterbury and an M.B.A. from Imperial College Management School.

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,300 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials. The Company anticipates three products manufactured from cell lines using the Selexis SUREtechnology Platform™ to be launched in 2012.

For more information, visit http://www.selexis.com

Media Contact:

Robert Meister
robert.meister(at)selexis(dot)com
(602) 953-1716


'/>"/>
SOURCE Selexis SA
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Selexis Launches Biosimilar Cell Line Development Program
2. Irvine Scientific and Selexis to Announce Results of Successful Collaboration
3. Selexis SA Doubles Cell Line Development Laboratory Space in Geneva, Switzerland
4. Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome
5. Selexis SA to Partner and Exhibit at BIO 2011 in Washington DC
6. Selexis SA to Give Away Euro 25,000 SUREvariant Screening Service Project at BIO 2011
7. CSL Limited Signs Commercial License Agreement with Selexis SA
8. Selexis SA to Present at Biotech Showcase 2012
9. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
10. Omeros Appoints David A. Mann to its Board of Directors
11. RainDance Technologies Appoints Olex Vice President, System Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/12/2019)... ... November 12, 2019 , ... Peggy Lillis Foundation (PLF) has ... healthcare-associated infection C. diff. The campaign, “See C. diff,” combines basic ... least 30,000 people in the U.S. each year. The campaign also features a ...
(Date:11/6/2019)... ... November 06, 2019 , ... ... off-the-record collaboration and dialogue, today announces its East/West CEO conference to ... San Francisco. , Kicking off the week of the J.P. Morgan ...
(Date:11/5/2019)... (PRWEB) , ... November 05, 2019 , ... Ole, a German Shepherd, was demonstrating signs ... stairs and jumping. Though his energy level and his willingness to play were normal, ... surgeon Dr. Holly Mullen of VCA Emergency Animal Hospital and Referral Center in ...
(Date:11/2/2019)... ... October 31, 2019 , ... drug360 graph, a breakthrough knowledge ... drug360 brings tellic’s expertise in biomedical language processing and machine learning to bear ... between genes, diseases, variants, phenotypes, and other biomedical entities. Researchers and analysts ...
Breaking Biology Technology:
(Date:11/6/2019)... ... 2019 , ... In October, Massachusetts stem cell biotechnology company ... a poorly disclosed deficiency in stem cell treatments. Throughout stem cell medical ... stem cells. This problem affects all patients receiving stem cell treatments, including ...
(Date:11/5/2019)... , ... November 05, 2019 , ... ... Dentistry, providing state-of-the-art cosmetic and restorative dentistry to Seattle, WA, including porcelain ... of Dental Surgery degree from the University of Washington, Dr. Kopp is passionate ...
(Date:10/30/2019)... ... October 29, 2019 , ... ... kits, for SIEMENS ATELLICA® analyzers, Order Numbers 701sa & 704sa. The kits, in ... UA, UTP, and UUN. , Each VALIDATE® kit, liquid, ready-to-use, and prepared using ...
Breaking Biology News(10 mins):